Karyopharm raises ~$50M via private placement and ATM; cash runway into late Q3 2026

Karyopharm Therapeutics Inc.

Private placement with RA Capital Management closed March 26: 1.03M shares at $6.785, pre-funded warrants for 3.39M shares, and warrants for 4.42M shares at $10.00 exercise.
Gross proceeds from private placement ~$30M; net proceeds from ATM sales of 2.99M shares ~$19.8M.
Post-transaction shares outstanding 22.54M plus pre-funded warrants for 4.01M shares.
Management expects existing liquidity, net product revenue, and license revenue to fund operations into late Q3 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.